| 000 | 01620 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516044627.0 | ||
| 264 | 0 | _c20110928 | |
| 008 | 201109s 0 0 eng d | ||
| 022 | _a1423-0232 | ||
| 024 | 7 |
_a10.1159/000328451 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBruzzone, M | |
| 245 | 0 | 0 |
_aSecond-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study. _h[electronic resource] |
| 260 |
_bOncology _c2011 |
||
| 300 |
_a238-46 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCA-125 Antigen _xblood |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xblood |
| 650 | 0 | 4 |
_aPlatinum _xtherapeutic use |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aCenturioni, M G | |
| 700 | 1 | _aGiglione, P | |
| 700 | 1 | _aGualco, M | |
| 700 | 1 | _aMerlo, D F | |
| 700 | 1 | _aMiglietta, L | |
| 700 | 1 | _aCosso, M | |
| 700 | 1 | _aGiannelli, F | |
| 700 | 1 | _aCristoforoni, P | |
| 700 | 1 | _aFerrarini, M | |
| 773 | 0 |
_tOncology _gvol. 80 _gno. 3-4 _gp. 238-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000328451 _zAvailable from publisher's website |
| 999 |
_c20986812 _d20986812 |
||